Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 75.15M | 73.24M | 65.56M | 53.30M | 41.81M | 31.72M |
Gross Profit | 57.80M | 56.35M | 50.16M | 41.28M | 32.05M | 23.57M |
EBITDA | 22.77M | 22.78M | 20.80M | 16.30M | 11.22M | 582.73K |
Net Income | 19.78M | 19.23M | 17.19M | 12.83M | 9.33M | 1.37M |
Balance Sheet | ||||||
Total Assets | 75.62M | 98.33M | 92.16M | 85.51M | 82.88M | 71.07M |
Cash, Cash Equivalents and Short-Term Investments | 42.78M | 52.23M | 49.76M | 57.96M | 62.50M | 51.98M |
Total Debt | 2.35M | 154.69K | 2.04M | 2.21M | 2.48M | 2.72M |
Total Liabilities | 11.28M | 11.51M | 20.74M | 11.84M | 10.71M | 9.68M |
Stockholders Equity | 64.34M | 86.82M | 71.42M | 73.67M | 72.17M | 61.38M |
Cash Flow | ||||||
Free Cash Flow | 14.00M | 17.62M | 5.46M | 8.17M | 10.52M | 5.18M |
Operating Cash Flow | 26.03M | 25.62M | 13.47M | 10.04M | 11.26M | 5.82M |
Investing Cash Flow | -12.26M | -8.82M | -8.01M | -1.37M | 648.24K | 246.97K |
Financing Cash Flow | -8.57M | -14.34M | -13.66M | -12.71M | 24.43K | 522.48K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $750.45M | 38.16 | 23.81% | 1.15% | 11.04% | 9.84% | |
65 Neutral | $767.70M | ― | -15.96% | ― | 22.60% | 41.26% | |
54 Neutral | $621.66M | ― | 26.25% | ― | ― | ― | |
52 Neutral | $547.07M | 45.80 | -36.78% | ― | 1.34% | -530.36% | |
52 Neutral | $7.49B | 0.22 | -61.87% | 2.28% | 16.62% | 1.08% | |
50 Neutral | $560.22M | ― | -19.79% | ― | 8.60% | -42.76% | |
43 Neutral | $505.12M | ― | -11.98% | ― | 46.69% | 46.68% |
On June 19, 2025, Iradimed Corporation held its Annual Meeting of Stockholders, where several key decisions were made. Stockholders elected five directors to the Board, ratified RSM US LLP as the independent auditor for 2025, and approved an advisory resolution on executive compensation. These outcomes reflect shareholder support for the company’s leadership and strategic direction, potentially impacting its governance and operational oversight.
The most recent analyst rating on (IRMD) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Iradimed stock, see the IRMD Stock Forecast page.